Akari Therapeutics appoints Kameel Farag as interim CFO

Akari Therapeutics Plc

Kameel Farag appointed interim CFO effective October 22, 2025; succeeds Torsten Hombeck.
Compensation: $18,000/month cash + $12,000 in RSUs for Oct-Dec 2025; increases in Jan-Feb 2026.
Consultant also entitled to 1.0% of capital raise proceeds up to $200,000 cap (0.5% after term).
Consulting agreement runs through February 16, 2026, with possible month-to-month extensions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.